Influx Healthtech FY26 Net Profit Rises 54% to Rs 205.41 Crore

Influx Healthtech Limited has reported its audited financial results for the fiscal year ended March 31, 2026. The company recorded a 54.3% year-on-year increase in net profit to Rs 2,054.13 lakh, up from Rs 1,331.40 lakh in the previous year. Revenue from operations for FY26 stood at Rs 14,683.36 lakh, marking a 40% growth compared to Rs 10,485.36 lakh in FY25.

Financial Performance Overview

The company’s earnings per share (EPS) improved to Rs 9.35 for FY26 from Rs 7.31 in the previous year. EBITDA for the full year reached Rs 2,986.13 lakh, a 45.2% increase, with an EBITDA margin of 20.3%. For the half-year ended March 31, 2026 (H2 FY26), revenue stood at Rs 8,006.90 lakh, while net profit was Rs 1,054.59 lakh.

Metric	FY26 (Rs. in Lakhs)	FY25 (Rs. in Lakhs)	YoY Change
Revenue from Operations	14,683.36	10,485.36	+40%
EBITDA	2,986.13	2,057.10	+45.2%
Net Profit	2,054.13	1,331.40	+54.3%
Basic EPS (Rs.)	9.35	7.31	+27.9%

Segment and Operational Highlights

The Nutraceuticals segment remained the dominant revenue contributor, accounting for approximately 90% of FY26 revenue with a 40.3% YoY growth to Rs 13,190.58 lakh. The Ayurvedic segment grew 88.9% to Rs 611.77 lakh, while the Cosmetics segment increased 15.8% to Rs 742.42 lakh.

Operationally, the company invested Rs 60 lakhs to boost tablet capacity and secured a 5-year FSSAI license for a new facility. It received compliance approval with Good Manufacturing Practices (GMP) to expand into the Tanzania market and incorporated Olahey Wellness Private Limited to manufacture Ready-to-Drink beverages.

Corporate Governance

The Board appointed M/s. Phirodia bafna & Associates as Internal Auditors for FY27. The statutory auditors, M/s V. B. Goel & Co., issued an unmodified opinion on the financial results. The company successfully listed on the NSE Emerge platform in June 2025, raising net proceeds of Rs 4,474.75 lakh.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.05%	+5.70%	-8.63%	+6.57%	+94.69%	+94.69%

Influx Healthtech has successfully passed a Good Manufacturing Practices (GMP) inspection conducted by the Tanzania Bureau of Standards at their manufacturing facility. This significant milestone demonstrates the company's adherence to international quality standards and regulatory compliance requirements.

GMP Inspection Results

The Tanzania Bureau of Standards conducted a comprehensive inspection of the company's manufacturing facility and confirmed that it meets all required GMP standards. This certification is crucial for pharmaceutical and healthcare companies as it validates their manufacturing processes, quality control systems, and overall operational excellence.

Inspection Details:	Information
Regulatory Body:	Tanzania Bureau of Standards
Inspection Type:	Good Manufacturing Practices (GMP)
Result:	Successfully Passed
Facility Status:	Meets GMP Standards

Significance of GMP Compliance

Good Manufacturing Practices represent a system of guidelines that ensure products are consistently produced and controlled according to quality standards. The successful completion of this inspection indicates that Influx Healthtech's facility maintains:

Proper manufacturing processes and procedures
Adequate quality control measures
Compliance with international regulatory standards
Systematic approach to product quality assurance

Market Impact

This GMP certification enhances the company's credibility in international markets and strengthens its position in the healthcare sector. The approval from Tanzania Bureau of Standards validates the company's manufacturing capabilities and opens opportunities for expanded operations in the East African region.

The successful inspection outcome reflects Influx Healthtech's commitment to maintaining high-quality manufacturing standards and regulatory compliance across its operations.